

Press release

8 January 2009

Curidium Medica Plc
("Curidium" or "the Company")

Resignation of Directors

The board of Curidium announces that non-executive directors, Dr Gosse Bruinsma and Dr Phyllis Whiteley, have resigned from the Board with immediate effect.

The board would like to express their thanks to both Dr Bruinsma and Dr Whiteley for their commitment to the Company during their time with Curidium and wishes them well for the future.

For further information:

Curidium Medica plc

Barry Porter, Chairman +44 (0) 20 7554 5100

Rob Smith, Finance Director +44 (0) 20 7554 5102

<http://www.curidium.com/>

FinnCap

Charles Cunningham +44 (0) 20 7600 1658

Notes to Editors

Curidium Medica plc

Curidium is a personalized medicine company identifying targeted medicines and companion diagnostics to treat patients more effectively.

Curidium's initial focus on diseases of the Central Nervous System has resulted in the identification of a blood diagnostic test, PsychINDx™, which classifies patients with schizophrenia/bipolar disorder into four subgroups. PsychINDx™ may have the potential to improve the treatment of patients with schizophrenia/bipolar disorder.

Many chronic human diseases are heterogeneous and their patient populations consist of mixed subgroups. Through the use of its proprietary analysis tool, Homomatrix®, Curidium aims to reveal different patient subgroups characterized by distinct underlying disease mechanisms potentially leading to the identification of:

1. Diagnostics for better identification and treatment within heterogeneous disease populations.
2. Improved therapies identified through novel drug targets.
3. Personalized medicines using companion diagnostics and targeted treatments.

Curidium aims to continue to use this approach to improve patient treatments in a variety of therapeutic areas. Further information on Curidium can be found at the Company's website: www.curidium.com.

Curidium Medica plc © 2001-2008. All rights reserved.

Studio 10, Tiger House, London WC1H 9BY, United Kingdom.

Email: info@curidium.com Tel.: +44 (0)20 7383 5345, Fax: +44 (0)20 7383 2973